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Patients (or Materials) and Methods: The study was conducted in 12 
healthy volunteers. Each patient received a 1-g single dose intrave-
nously of sulbactam, after which PK studies were carried out, using 
a Monte Carlo simulation to determine the probability of attaining 
a specific pharmacodynamic target.
Results: The population PKs of sulbactam were; k12 = 0.637 (2.003) 
h-1, k21 = 0.663 (1.736) h-1, k13 = 8.626 (2.035) h-1, k31 = 5.424 
(2.058) h-1 ke = 3.223 (1.380) h-1, CL = 11.903 (1.978) L/h and V 
= 3.693 (1.434) L. The PTAs for selected regimens over a range of 
MICs were as follows:
Conclusion: The high PTA (≥ 90%) achieving 40% T> MIC for an 
MIC of 8 mg/L was observed when sulbactam was administered by a 
4-hour infusion of 3 g q8h, which would be an alternative treatment 
option for less-susceptible pathogens.
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Introduction: Piperine is the main pungent alkaloid present in the 
fruits of black pepper (Piper nigrum) and long pepper (Piper longum).
In traditional medicine, black pepper has been used as an analgesic 
and anti-inflammatory agent and in the treatment of epilepsy and 
snake venom poisoning. Piperine also has been reported as an inhibi-
tor against several cytochrome P-450–mediated pathways and Phase 
II metabolism as well as P-glycoprotein. This study was carried out 
to investigate the effect of piprine on the pharmacokinetics of dom-
peridone after acute and chronic administration in rats.
Patients (or Materials) and Methods: Animals received a single dose 
of domperidone (20 mg/kg, p.o.) alone or together with piperine (60 
mg/kg, p.o.). Similarly, the same doses of domperidone alone or when 
it was given together with piperine were administered to rats chroni-
cally for 5 days. Plasma samples were collected at 0.25, 0.5, 1.0, 2.0, 
3.0, 4.0, 6.0, 8.0, 10.0, and 12.0 hours after drug administration. 
The concentrations of domperidone in the plasma were measured 
using an HPLC method.
Results: The concomitant administration of piperine with dom-
peridone acutely or chronically resulted in a significant (P < 0.05) 
increase in the maximum plasma concentration (Cmax), the mean 
area under the plasma concentration–time curve (AUC), and the elim-
ination half-life (t½) of domperidone compared with those obtained 
for domperidone alone.
Conclusion: The concurrent administration of piprine with dom-
peridone to rats produced a significant increase in the plasma levels 
of the latter. However, further studies are needed to determine the 
possible mechanism(s) involved in this pharmacokinetic interaction.
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Introduction: Introducing of a standard drug monitoring for digoxin, 
a digitalis glycoside using in heart failure, considerably reduce the 
incidences of digoxin toxicity. The need for measurement of digoxin 
concentrations and knowledge about bioavailability of the given 
preparation arise from the low therapeutic index of digoxin and 
its concentration-dependent toxicity. The recommended therapeutic 
range (1.0–2.5 nmol/L) reflects significant increase in the risk of toxic-
ity that occurs with serum concentrations over 2.6 nmol/L. Choosing 
a proper analytical method for digoxin bioavailability evaluation is 
essential due to digoxin-like immunologic factor (DLIF) and others 
interfering substances that overestimate serum digoxin concentration 
which may be a significant clinical problem.
Patients (or Materials) and Methods: The study was performed on 
24 healthy volunteers in accordance with GCP and legal require-
ments. Digoxin tablets were administered as a single dose of 0.5 mg. 
Pharmacokinetic profiles were plotted up to 60 hours after dosing. 
Determination of digoxin concentration in serum samples was per-
formed by immunoenzymatic method by using the Emit® 2000 Digoxin 
Assay (Siemens Healthcare Diagnostics). EMIT is a homogeneous 
enzyme immunoassay intended for use in the quantitative analysis of 
digoxin in human serum or plasma. The method was fully validated 
according to the international guidelines. Original solutions of digoxin 
were used as calibration standards. Lower limit of quantification was 
set at the concentration of 0.1 ng/mL that is sufficient for human phar-
macokinetic evaluation. Standard pharmacokinetic and bioavailabil-
ity parameters in single-dose regiment (AUCt, AUCinf, Cmax, Tmax, 
MRT, t1/2) were calculated by a noncompartmental method.
Results: Study results, including t1/2 and other bioavailability 
parameters, were in agreement with the reference data. Mean AUCinf 
was 33.42 (10.13) ng*h/mL, while AUCt was 23.93 (6.70) ng*h/
mL. Cmax was observed as 3.24 (0.77) ng/mL but occurred at dif-
ferent Tmax (range, 0.5–2.5 hours). The intersubject variability was 
similar in case of AUC and Cmax (range, 23.80%–30.31%). The 
high variability of Tmax was observed (49.33%). Cmax exceed the 
recommended therapeutic ranges in most cases due to administration 
of a high dose of the tested drug. Digoxin tablets elimination half-life 
in healthy volunteers, even after single dose administration is high 
(32.78 [6.48] hours) as well as MRT (44.14 [8.34] hours).
Conclusion: The study results have confirmed that the EMIT method 
was appropriate for assessment digoxin bioavailability and can be 
used not only as reliable screening test but also in bioavailability and 
bioequivalence evaluation.
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Dosage regimen MIC (mg/L) PTA of T> MIC
20%
40% 30%
1 g q8h (1/2/3/4 h infusion) 1 0.17/0.99/0.99/0.99
2 0.00/0.21/0.99/0.99
4 0.00/0.00/0.44/0.99
2 g q8h (1/2/3/4 h infusion) 1 0.04/0.99/0.99/0.97
2 0.00/0.06/0.99/0.97
4 0.00/0.00/0.20/0.97
3 g q8h (1/2/3/4 h infusion) 4 0.06/0.96/0.88/0.73
8 0.00/0.00/0.87/0.73
4 g q8h (1/2/3/4 h infusion) 4 0.00/0.00/0.02/0.72
8 0.43/1.00/0.99/0.99
3/6/9/12 g q24h (continuous 
infusion)
4 0.11/0.46/0.99/0.99 
0.02/0.07/0.66/0.99 
0.17/0.99/0.99/0.99 
0.00/0.21/0.99/0.99
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Introduction: There are several generic formulations of lamotrigine 
in Serbia that are widely used in the treatment of patients with epi-
lepsy. The reduction of medical costs with use of generic formulations 
has potential risk because of the nature of disease, and it is necessary 
to investigate bioequivalence of each of generic formulations.
Aim: Comparison of the efficacy of the reference and generic for-
mulation of lamotrigine and theinvestigation of lamotrigine serum 
concentrations variation. Date were compared with in vitro results 
of dissolution profiles of the reference and generic tablet formulation.
Patients (or Materials) and Methods: Lamotrigine steady-state con-
centrations were determined by high-performance liquid chromatog-
raphy. In clinical study 16 patients participated, of whom 9 received 
reference formulation and 7 patients received generic formulation. 
Dissolution characteristics were evaluated at 3 points at physiologic 
pH range (pH 1.2, pH 4.5, pH 6.8), and difference (f1) and similarity 
(f2) tests were applied to dissolution data.
Results: The relationship between lamotrigine serum concentration 
(µg/mL) and lamotrigine dose (mg/kg/d) were linear in both formu-
lations (r2 = 0.78484 original and r2 = 0.83417 generic). There are 
statistically significant lower lamotrigine serum concentrations in 
patient treated with original formulation (3.97 [4.1] µg/mL) than 
those in patients treated with generic formulations (5.78 [2.7] µg/
mL). No dose-dependent adverse effects appeared in the patients, 
though patients treated with generic drug were receiving higher doses 
due to assumption that they are less potent. Brand drug had a lower 
standard deviation (SD) and data scattering because, as the dissolu-
tion data showed, it is less influenced by pH changes. Further dissolu-
tion profiles of 2 formulations were only similar in pH 1.2 medium.
Conclusion: Investigation showed equal efficacy of 2 lamotrigine 
formulations, and the variations in plasma concentrations are prob-
ably due to individual characteristics of patients and differences in 
liberation rate of drugs in 2 formulations. It can be claimed that even 
if there are differences in dissolution profiles of 2 drugs they can have 
equal therapeutic efficacy.
Financial Source: This work has been supported by Ministry of 
Science and Technology development of Serbia N041012.
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Introduction: Tacrolimus, a potent immunosuppressant, is used for the 
prevention of allograft rejection in organ transplantation. Tacrolimus 
trough concentration (TTC) is still widely used as a guide to individual-
izing tacrolimus dose requirements in renal transplantation. The aim 
was to investigate the effect of patient’s gender on TTC in renal trans-
plant recipients on quaternary immunosuppressive therapy (tacrolimus, 
mycophenolate mofetil, prednisone, and anti–T lymphocyte globulin).
Patients (or Materials) and Methods: Present retrospective case series 
study involved 138 male and 70 female patients subjected to renal 
transplantation. The outpatient examination, recorded in the data-
base of patients from year 2006 to 2008, as the unit of monitoring, 
contained such 3255 male and 1756 female examinations. Tacrolimus 
through concentrations were measured by fluorescence polarisation 
immunoassay (FPIA, TDx, Abbott Laboratories, Chicago, Illinois).
Results: Average TTC in outpatient examinations of male patients 
(7.098 [3.4870] ng/mL) were significantly higher (t = 2.432, P = 
0.015) compared with female transplant recipients (6.852 [3.2726] 
ng/mL).In 25.3% of male examinations, TTC were within the “sub-
therapeutic” range (< 5 ng/mL), while 28.3% of female examinations 
were within the same range; the difference was statistically signifi-
cant. On the other hand, the number of examinations in which the 
TTC were “over the therapeutic” range (> 10 ng/mL) in females were 
significantly lower than in males.
Conclusion: Our results indicated TTC as a useful guide in pointing 
out to potentially relevant influence of sex on its pharmacokinetics, 
what should be routinely considered and further studied.
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Introduction: Pharmacokinetic data of GCV are limited in HSCT 
patients under preemptive therapy and its induced hematologic tox-
icity still problematic.The aim of this study was to evaluate the PK 
of GCV after single and multiple doses in HSCT patients with CMV 
infection and to identify correlation between PK parameters and 
hematologic toxicity.
Patients (or Materials) and Methods: A PK study was conducted 
between October 2008 and December 2009 at MG hospital in Beirut, 
after IV GCV treatment in HSCT recipients with CMV infection. 
CMV disease was recognized by the combination of clinical signs and 
antigenemia. Patients received 1-hour infusion of 5 mg/kg q 12h for 
14 days, and a complete PK study was performed at days 1, 7, and 14. 
A compartmental and no PK analysis were performed, and plasma 
GCV was analyzed by an HPLC validated method with UV detection. 
An ANOVA analysis associated to Freadman test was performed to 
compare the mean PK parameters. The 95% CI was calculated for 
some parameters and P < 0.05 was considered significant.
Results: Twelve patients were enrolled in this study. A significant 
difference in creatinine clearance (Clcr) and trombecytopenia, 
TTC (ng/mL)
Tacrolimus Trough Concentration (TTC); 
No. (%) P value (Chi-square test)
Male Female
< 5 824 (25.3) 497 (28.3) 0.0241
5–10 1931 (59.3) 1028 (58.5) 0.6101
> 10 500 (15.4) 231 (13.2) 0.0386
3255 (100.0) 1756 (100.0)
